RANKL and RANK as novel therapeutic targets for arthritis

Current Opinion in Rheumatology

Volumn 15, Issue 3, 2003, Pages 280-287

  Nakashima, Tomoki ^a   Wada, Teiji ^a   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

BOLUS INJECTION; BONE DESTRUCTION; BONE EROSION; BONE INJURY; BONE REMODELING; CARTILAGE DEGENERATION; CELL COMMUNICATION; CHRONIC ARTHRITIS; DENDRITIC CELL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG INHIBITION; ESTROGEN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; LACTATION; MAMMARY GLAND; METASTASIS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OVARY FUNCTION; PERIARTICULAR JOINT DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SINGLE DRUG DOSE; SYNOVITIS; T LYMPHOCYTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE REMODELING; CARRIER PROTEINS; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; GLYCOPROTEINS; HUMANS; LIGANDS; MALE; OSTEOCLASTS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0038746729     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200305000-00016     Document Type: Review

References (56)

1. Suda T, Takahashi N, Udagawa N, et al.: Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
2. Ross FP: RANKing the importance of measles virus in Paget's disease. J Clin Invest 2000, 105:555-558.
3. Roodman GD: Cell biology of the osteoclast. Exp Hematol 1999, 27:1229-1241.
4. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176. First demonstration that RANKL/OPGL/RANK might have a role in osteoclasts
5. Yasuda H, Shima N, Nakagawa N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
6. Wong BR, Rho J, Arron J, et al.: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
7. Kong YY, Yoshida H, Sarosi I, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323. First genetic proof that RANKL/OPGL is indeed the critical factor for osteoclast and lymph node development.
8. Nakagawa N, Kinosaki M, Yamaguchi K, et al.: RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
9. Anderson DM, Maraskovsky E, Billingsley WL et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
10. Fata JE, Kong YY, Li J, et al.: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
11. Nakashima T, Kobayashi Y, Yamasaki S, et al.: Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000, 275:768-775.
12. Dougall WC, Glaccum M, Charrier K, et al.: RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
13. Li J, Sarosi I, Yan XQ, et al.: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571.
14. Simonet WS, Lacey DL, Dunstan CR, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319. Cloning and first functional analysis of OPG.
15. Yasuda H, Shima N, Nakagawa N, et al.: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337. Cloning and functional analysis of OPG
16. Bucay N, Sarosi I, Dunstan CR, et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
17. Mizuno A, Murakami A, Nakagawa N, et al.: Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. Gene 1998, 215:339-343.
18. Zhang YH, Heulsmann A, Tondravi MM, et al.: Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001, 276:563-568.
19. Hofbauer LC, Khosla S, Dunstan CR, et al.: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370. Demonstration that estrogen can regulate OPG expression as potential molecular explanation for postmenopausal bone loss.
20. Saika M, Inoue D, Kido S, et al.: 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001, 142:2205-2212.
21. Kong YY, Feige U, Sarosi I, et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309. First paper that T cell-derived RANKL can regulate osteoclast differentation and hat OPG blocks bone loss in adjuvant arthritis in rats.
22. Kim N, Odgren PR, Kim DK, et al.: Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000, 97:10905-10910.
23. Vidal NO, Brandstrom H, Jonsson KB, et al.: Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 1998, 159:191-195.
24. Teng YT, Nguyen H, Gao X, et al.: Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000, 106:59-67.
25. Brandt J, Haibel H, Cornely D, et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346-1352.
26. Arron JR, Choi Y: Bone versus immune system. Nature 2000,408:535-536.
27. Takayanagi H, Ogasawara K, Hida S, et al.: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605. Demonstration of a possible negative regulation of RANK signaling by interferon γ.
28. Horwood NJ, Elliott J, Martin TJ, et al.: IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001, 166:4915-4921.
29. Abu-Amer Y: IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J Clin Invest 2001, 107:1375-1385.
30. Bendixen AC, Shevde NK, Dienger KM, et al.: IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 2001, 98:2443-2448.
31. Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
32. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
33. Bendele A, McComb J, Gould T, et al.: Animal models of arthritis: relevance to human disease. Toxicologic Patholology 1999, 27:134-142.
34. Panayi GS, Lanchbury JS, Kingsley GH: The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992, 35:729-735.
35. Campagnuolo G, Bolon B, Feige U: Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002, 46:1926-1936.
36. Bolon B, Campagnuolo G, Feige U: Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci 2002, 59:1569-1576.
37. Conway JG, Wakefield JA, Brown RH, et al.: Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995, 182:449-457.
38. Campagnuolo G, Bolon B, Feige U: Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002, 46:1926-1936.
39. Hsu H, Lacey DL, Dunstan CR, et al.: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999, 96:3540-3545.
40. Komuro H, Olee T, Kuhn K, et al.: The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 2001, 44:2768-2776.
41. Benoist C, Mathis D: A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2000, 2:90-94.
42. Kouskoff V, Korganow AS, Duchatelle V, et al.: Organ-specific disease provoked by systemic autoimmunity. Cell 1996, 87:811-822.
43. Pettit AR, Ji H, von Stechow D, et al.: TRANCE/RANKL knockout mice are protected from bone erosion in the K/BxN serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699. Demonstration that RANKL/RANK regulate bone loss in an antibody mediated model of arthritis, that is, T cells are not necessarily required for RANKL-mediated crippling.
44. Ji H, Pettit A, Ohmura K, et al.: Critical roles for interleukin 1 and tumor necrosis factor a in antibody-induced arthritis. J Exp Med 2002, 196:77-85.
45. Keffer J, Probert L, Cazlaris H, et al.: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10:4025-4031.
46. Redlich K, Hayer S, Maier A, et al.: Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002, 46:785-92.
47. Romas E, Sims NA, Hards DK et al.: Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427.
48. Mori H, Kitazawa R, Mizuki S, et al.: RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol 2002, 117:283-292.
49. Kotake S, Udagawa N, Hakoda M, et al.: Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012.
50. κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 2001, 40:623-630.
51. Kotake S, Udagawa N, Hakoda M, et al.: Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012.
52. Ziolkowska M, Kurowska M, Radzikowska A, et al.: High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment Arthritis Rheum 2002, 46:1744-1753.
53. Gravallese EM: Bone destruction in arthritis. Ann Rheum Dis 2002, 61:84-86.
54. Fye KH: New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs. Postgrad Med 1999, 106:82-85.
55. Graninger WBSmolen JS: One-year inhibition of tumor necrosis factor-alpha: a major success or a larger puzzle? Curr Opin Rheumatol 2001, 13:9-13.
56. Oliveri MB, Mautalen CA, Rodriguez Fuchs CA, et al.: Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J 1991, 39:45-48.